Wells Fargo raised the firm’s price target on Globus Medical (GMED) to $79 from $66 and keeps an Overweight rating on the shares. The firm notes the company delivered impressive Q3 beat with EPS of $1.18 vs. consensus 78c. Raised 2025 targets reflect Nevro accretion earlier than expected and U.S. Spine stabilization.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $90 from $80 at Piper Sandler
- Globus Medical upgraded to Buy from Neutral at BofA
- Cautious Optimism: Hold Rating for Globus Medical Amid Strong Performance and Revenue Concerns
- Globus Medical upgraded to Buy from Hold at Truist
- Globus Medical’s Strong Q3 2025 Performance and Growth